Skyrizi defies J&J rival Icatide as AbbVie raises full‑year 2026 guidance

AbbVie has raised its full-year revenue and earnings guidance for 2026, driven largely by strong momentum for its immunology drugs Skyrizi and Rinvoq, even as longer-established Humira sales continue to decline.
Skyrizi generated $4.48–$4.5 billion in Q1 2026, up roughly 29–30% operationally, contributing to immunology portfolio growth of about 16–18%.
Overall net revenues for Q1 2026 reached about $15 billion, up ~12.4% versus prior year, beating analyst expectations.
AbbVie now expects about $67.3 billion in total net revenues for 2026, an increase of $300 million from prior guidance, and has raised adjusted EPS guidance to $14.08–$14.28 per share.
Skyrizi’s full‑year 2026 revenue guidance has been raised to $21.6 billion, and Rinvoq’s to $10.2 billion, reflecting continued strong demand and market share gains in psoriasis and inflammatory bowel disease.
AbbVie has cited Skyrizi’s clinical profile and market leadership as limiting the competitive impact of Johnson & Johnson’s newer entrant Icatide (icovir/icatyde) in psoriasis, with the vast majority of Icatide’s share coming from other oral therapies rather than Skyrizi.
Skyrizi and Rinvoq together are on track to exceed $31 billion in combined annual sales in 2026, already surpassing AbbVie’s own 2027 long‑term guidance target by about $500 million, underscoring the franchise’s importance to AbbVie’s growth story beyond Humira.